DarioHealth Corp.
NASDAQ:DRIOMedical - Diagnostics & Research
-$0.12 today
- Market cap
- $50.27M
- Beta
- 1.08
- P/E (TTM)
- 5.5
- EPS (TTM)
- $1.26
Volume 0.01M
Average 0.01M
DRIO Deferred Revenue
Payments received for goods or services the company will deliver within the next year.
DarioHealth Corp.NASDAQ: DRIO
Deferred Revenue · Q1 FY2026 · quarter ended Mar 2026
Deferred revenue falls 61.6% from a year ago
Deferred revenue stood at $501K at the end of Q1 FY2026, down 61.6% from a year earlier and down 29.8% from the prior quarter. Over 3 fiscal years it compounded at -18.5% a year.
Context
- Deferred revenue amounted to 0.5% of total assets at the end of Q1 FY2026, down 0.6 pp from a year earlier.
- Deferred revenue increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether deferred revenue keeps falling in the next quarterly balance sheet after a -61.6% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Deferred Revenue history
USD · from the balance sheet
- Latest · FY2025
- 714K USD
- Year-over-year change
- -54.9%
- 4-year CAGR
- -12.1%
| Period | Period end | Deferred Revenue | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 714K | -54.9% |
| FY2024 | 2024-12-31 | 1.58M | +58.8% |
| FY2023 | 2023-12-31 | 997K | -24.5% |
| FY2022 | 2022-12-31 | 1.32M | +10.5% |
| FY2021 | 2021-12-31 | 1.2M | — |
Deferred Revenue vs competitors
How DRIO compares with its peers on the latest reported figures
- DRIO's Mar 2026 deferred revenue of $501K is the 4th highest of the 11 companies compared; the peer median is $137.5K.
- Its year-over-year change of -61.6% is the 4th highest of 5, against a peer median of -57.7%.
- Deferred revenue amounts to 0.5% of total assets for DRIO, versus a peer median of 0.0%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $16.33M | +7.1% | — | 2.1% | |
| Mar 2026 | $5.92M | -56.4% | +78.8% | 1.7% | |
| Mar 2026 | $3.01M | -90.1% | +31.1% | 0.3% | |
| Mar 2026 | $501K | -61.6% | -18.5% | 0.5% | |
| Mar 2026 | $450K | -58.9% | +18.4% | 0.2% | |
| Mar 2026 | $275K | — | — | 0.1% | |
| Mar 2026 | $0 | — | — | 0.0% | |
| Mar 2026 | $0 | — | — | 0.0% | |
| Mar 2026 | $0 | — | — | 0.0% | |
| Mar 2026 | $0 | — | — | 0.0% | |
NNNNAnbio Biotechnology Class A Ordinary Shares | Dec 2025 | $0 | — | — | 0.0% |
| Peer median (excluding DRIO) | $137.5K | -57.7% | +31.1% | 0.0% | |
Competitors are the stored peer set for DRIO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 36M | 49.36M | 36.8M | 27.76M | 26.25M |
| Short-term Investments | 0 | 0 | 0 | 697K | 0 |
| Net Receivables | 1.79M | 6.42M | 3.64M | 5.35M | 2.67M |
| Inventory | 6.23M | 7.96M | 5.06M | 4.75M | 4.32M |
| Other Current Assets | 0 | 887K | 292K | 175K | 0 |
| Total Current Assets | 45.61M | 65.52M | 47.33M | 40.53M | 34.81M |
| Property, Plant & Equipment (Net) | 989K | 1.99M | 1.87M | 1.77M | 1.27M |
| Goodwill | 41.64M | 41.64M | 41.64M | 57.43M | 57.43M |
| Intangible Assets | 12.46M | 9.92M | 5.4M | 18.76M | 15.93M |
| Long-term Investments | 20K | 6K | 6K | 0 | 80K |
| Tax Assets | 0 | (6K) | 0 | 0 | 0 |
| Other Non-current Assets | 57K | 117K | 143K | 392K | 562K |
| Total Non-current Assets | 55.17M | 53.67M | 49.06M | 78.36M | 75.27M |
| Total Assets | 100.77M | 119.19M | 96.39M | 118.88M | 110.08M |
| Account Payables | 5.11M | 2.32M | 1.13M | 3.05M | 2.93M |
| Short-term Debt | 266K | 8.82M | 3.95M | 5.45M | 430K |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 1.2M | 1.32M | 997K | 1.58M | 714K |
| Other Current Liabilities | 4.4M | 2.19M | 4.07M | 4.11M | 5.25M |
| Total Current Liabilities | 14.38M | 19.35M | 12.49M | 16.64M | 9.32M |
| Long-term Debt | 0 | 18.11M | 24.59M | 23.47M | 30.75M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 825K | 910K | 276K | 5.99M | 1.51M |
| Total Non-current Liabilities | 846K | 19.84M | 25.75M | 30.23M | 32.83M |
| Total Liabilities | 15.22M | 39.19M | 38.25M | 46.87M | 42.15M |
| Common Stock | 2K | 3K | 3K | 4K | 4K |
| Retained Earnings | (222.01M) | (285.85M) | (349.36M) | (390.34M) | (452.08M) |
| Accumulated OCI | 0 | 0 | 0 | 0 | 0 |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 85.55M | 80M | 58.14M | 72.02M | 67.92M |
| Total Debt | 287K | 28.05M | 29.54M | 30.19M | 31.75M |
| Net Debt | (35.71M) | (21.31M) | (7.26M) | 2.43M | 5.5M |
DarioHealth Corp.
NASDAQ:DRIO
Intrinsic Alpha fair value
Locked
Current Price
$5.13
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.